Colchicine After MI: COLCOT's Result Against the Trial That Didn't Repeat It
The trial that established colchicine's post-MI benefit and the newer, larger trial that didn't reproduce it were run on nearly identical populations. The disagreement between them is current, real, and unresolved by anything in her chart.
S.F., a 52-year-old woman, has worked as a museum conservator for over twenty years, spending her days on close, patient restoration work that she says has made her unusually calm during her own recovery. Six weeks ago she had an NSTEMI, was found to have a lesion in the left circumflex artery, and received a stent; she has since started cardiac rehab and, somewhat to her own surprise, signed up to train for her first half-marathon, framing it as something concrete to work toward while the rest of her recovery feels abstract. Her GDMT is optimized — high-intensity statin, ACE inhibitor, beta-blocker, dual antiplatelet therapy — and at today's rehab follow-up her cardiologist raised colchicine as a possible addition.
The case for it rests on COLCOT, which randomized patients within 30 days of MI to colchicine 0.5 mg daily and showed a 23% reduction in major adverse cardiovascular events, and on LoDoCo2's similar benefit in stable coronary disease — together the basis for colchicine's current guideline-level recommendation in this setting. What complicates recommending it to her specifically is CLEAR-SYNERGY, a larger, more recent trial randomizing over seven thousand post-MI patients to the same 0.5 mg dose, which found no benefit at all (9.1% versus 9.3%) despite lowering inflammatory markers — though it randomized patients within 72 hours of their PCI rather than COLCOT's within 30 days, a difference in timing that is itself one of the leading proposed explanations for the divergence — a genuinely unsettled result in the field, with COLCOT's own lead investigator publicly disputing whether CLEAR-SYNERGY's null finding should be read as the more reliable one. Her training plan adds a separate, practical layer: colchicine's most common side effects are gastrointestinal upset and myalgia, either of which could complicate a distance-running program she has only just started.
At the cardiac rehab follow-up
COLCOT and LoDoCo2 together are the basis for colchicine's current place in post-MI secondary prevention, and the pooled meta-analysis across both plus smaller trials shows a consistent MACE reduction. At six weeks she's just outside COLCOT's own 30-day enrollment window — median time to randomization there was 14 days — but LoDoCo2's chronic coronary disease population covers where she is now. I'd start colchicine 0.5 mg daily.
I think we have to name CLEAR-SYNERGY directly rather than treat it as a footnote. It's larger than COLCOT, more recent, tested the identical dose in post-MI patients, and found nothing — even though it confirmed colchicine did what it's supposed to do to inflammatory markers. That's not a trial that failed to detect a real effect for lack of power.
I'll say plainly that Tardif, who led COLCOT, has publicly argued CLEAR-SYNERGY's null result reflects a COVID-era interaction rather than colchicine not working, and Jolly, who led CLEAR-SYNERGY, has countered that COLCOT accrued roughly 300 events against CLEAR-SYNERGY's 649 and that its benefit was driven largely by urgent hospitalization for angina rather than by hard outcomes. Neither argument has settled it.
Given that the trial evidence genuinely disagrees with itself, I don't think either starting or withholding colchicine is the wrong call here — but I do think her training plan matters practically. GI upset and myalgia are colchicine's most common side effects, and either could plausibly get blamed on overtraining instead of the drug during a first half-marathon build-up. I'd start it, but time-limited to roughly the two-year window COLCOT itself used rather than committing to it indefinitely, and revisit explicitly when her rehab program ends rather than letting it become a permanent, unexamined addition.
Colchicine 0.5 mg daily started, with an explicit plan to reassess at roughly the two-year mark rather than continue indefinitely by default. GDMT otherwise unchanged.
Not resolved by this decision, and stated to her as such:
Colchicine may eventually be recognized as ineffective for this indication, and the 2-year stopping point would prove to have been the right call for the wrong-turning-out-right reason.
Continuing past 2 years could reasonably be reconsidered rather than stopped on schedule.
She was told the field itself hasn't resolved this, and that starting the drug didn't require her physicians to agree on which trial to believe.